Reduction of hemolytic blood damage with dextran

Lijana, Robert C.; Williams, Michael C.

doi:10.1002/aic.690330718

Cited by 3 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…32,33 The haemolytic profiles reported in Figure 4 show that, similarly to dextran, Pull-(GGPNle-ϕ-PTX)- The cell viability profiles reported in Figure 5 show that the cell proliferation was inhibited by both Pull-(GGPNle-ϕ-PTX)-(PEG-ALN) and Pull-(GGPNle-ϕ-PTX)-(PEG-COOH). The data reported in Table II show that, with the exception of K7M2 cells, the IC 50 obtained with Pull-(GGPNle-ϕ-PTX)-(PEG-ALN) was about 5-20 times higher than that obtained with PTX and the IC 50 of Pull- 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 than PTX and 30 times more active than Pull-(GGPNleϕPTX)-(PEG-COOH).…”

Section: Pullulan Conjugates Do Not Cause Rbc Lysismentioning

confidence: 84%

See 1 more Smart Citation

Novel Pullulan Bioconjugate for Selective Breast Cancer Bone Metastases Treatment

et al. 2015

View full text Add to dashboard Cite

A novel polysaccharide bioconjugate was designed to selectively target breast cancer bone metastases using a bisphosphonate moiety (alendronate, ALN). Paclitaxel (PTX) was first covalently conjugated to pullulan (Pull) through a Cathepsin K-sensitive tetrapeptide spacer followed by a self-immolative aminobenzyl alcohol spacer to obtain Pull-(GGPNle-φ-PTX). ALN was then conjugated to the polymeric backbone of Pull-(GGPNle-φ-PTX) via a PEG spacer. The final bioconjugate Pull-(GGPNle-φ-PTX)-(PEG-ALN) was found to assemble into colloidal spherical structures, which were physically and chemically stable under physiological conditions. In vitro studies showed that Pull-(GGPNle-φ-PTX)-(PEG-ALN) had strong affinity for hydroxyapatite, which simulates the bone tissue. Paclitaxel was rapidly released from the bioconjugate by Cathepsin K cleavage under pathological conditions. All studies performed using human MDA-MB-231-BM (bone metastases-originated clone), murine 4T1 breast cancer cells, murine K7M2, and human SAOS-2 osteosarcoma cells showed that the bioconjugate exerted an enhanced antiproliferative activity compared to the conjugate without the ALN. Furthermore, the nanoconjugate inhibited the migration of cancer cells and further displayed potent anti-angiogenic activity. In conclusion, the results showed that this conjugate has an excellent potential for selective treatment of bone neoplasms such as breast cancer bone metastases and osteosarcoma.

show abstract

Section: Pullulan Conjugates Do Not Cause Rbc Lysismentioning

confidence: 84%

“…Hemocompatibility studies were carried out by incubating rat red blood cells (RBC) with Pull-(GGPNle-φ-PTX)-(PEG-ALN) or equivalent PTX and ALN amounts in 1:1:8 ethanol/Cremophor EL. Dextran and poly(ethylene imine) (PEI) were also tested as negative and positive control for hemolysis, respectively. , …”

Section: Resultsmentioning

confidence: 99%

Novel Pullulan Bioconjugate for Selective Breast Cancer Bone Metastases Treatment

et al. 2015

View full text Add to dashboard Cite

show abstract

Can blood additives reduce hemolysis in an artificial heart?

Garrison

Frangos

Geselowitz

et al.

1993 IEEE Annual Northeast Bioengineering Conference

View full text Add to dashboard Cite

A New Mock Circulatory Loop and Its Application to the Study of Chemical Additive and Aortic Pressure Effects on Hemolysis in the Penn State Electric Ventricular Assist Device

et al. 1994

View full text Add to dashboard Cite

A new mock circulatory loop was developed for hemolysis studies associated with the Penn State electric ventricular assist device (EVAD). This flow loop has several advantages over previously designed loops. It is small enough to accommodate experiments in which only single units of blood are available, it is made out of biocompatible materials, it incorporates good geometry, and it provides normal physiological pressures and flows to both the aortic outlet and the venous inlet of the pumping device. Experiments with reduced aortic pressure but normal cardiac output showed that hemolysis in a loop with normal aortic blood pressure was significantly higher than that in a loop with lowered aortic pressure, thereby illustrating the importance of maintaining loop pressures as close as possible to those found in vivo. This data also imply that blood traveling through the left ventricle in an artificial heart may be subject to higher hemolysis rates than that traversing the right ventricle. Another set of experiments to determine the effects of 4 hemolysis or drag-reducing agents (Pluronic F-68, Dextran-40, Polyox WSR-301, and Praestol 2273TR) on blood trauma due to the EVAD and associated valves was performed. Results indicated that none of the additives significantly reduced hemolysis under the conditions found in the mock loop. Finally, a compilation of data gathered in these experiments showed that the index of hemolysis (IH) is dependent on hematocrit (HCT), which suggests that another parameter, IH/HCT, may be more suited to the quantification of hemolysis.

show abstract

Reduction of hemolytic blood damage with dextran

Cited by 3 publications

References 23 publications

Novel Pullulan Bioconjugate for Selective Breast Cancer Bone Metastases Treatment

Novel Pullulan Bioconjugate for Selective Breast Cancer Bone Metastases Treatment

Can blood additives reduce hemolysis in an artificial heart?

A New Mock Circulatory Loop and Its Application to the Study of Chemical Additive and Aortic Pressure Effects on Hemolysis in the Penn State Electric Ventricular Assist Device

Contact Info

Product

Resources

About